Molecular modelling studies on 2-substituted octahydropyrazinopyridoindoles for histamine H2 receptor antagonism

SAR and QSAR in Environmental Research

Volumn 26, Issue 7-9, 2015, Pages 739-755

  Saxena, M ^a   Bhunia, S S ^b   Saxena, A K ^c  

^a AMITY UNIVERSITY   (India)

^b Affiliated to Uttarakhand Technical University   (India)

^c CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

antihistaminic H2; docking; famotidine pharmacophore; histamine H2 blocker; homology modelling; octahydropyrazino pyridoindoles

Indexed keywords

DISEASES; PROTEINS;

ADRENERGIC RECEPTORS; ANTIHISTAMINIC H2; DOCKING; FAMOTIDINE PHARMACOPHORE; HISTAMINE H2 BLOCKER; HISTAMINES; HOMOLOGY MODELING; MODE OF BINDING; OCTAHYDROPYRAZINO-PYRIDOINDOLE; PHARMACOPHORES;

CRYSTAL STRUCTURE;

CIMETIDINE; FAMOTIDINE; HISTAMINE H2 RECEPTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; INDOLE DERIVATIVE; METIAMIDE; PYRAZINE DERIVATIVE; PYRIDINE DERIVATIVE; RANITIDINE;

CHEMISTRY; COMPUTER SIMULATION; HUMAN; MOLECULAR DOCKING; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION;

CIMETIDINE; COMPUTER SIMULATION; FAMOTIDINE; HISTAMINE H2 ANTAGONISTS; HUMANS; INDOLES; METIAMIDE; MOLECULAR DOCKING SIMULATION; PYRAZINES; PYRIDINES; RANITIDINE; RECEPTORS, HISTAMINE H2; SEQUENCE HOMOLOGY, AMINO ACID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84946491440     PISSN: 1062936X     EISSN: 1029046X     Source Type: Journal    
DOI: 10.1080/1062936X.2015.1088572     Document Type: Article

References (53)

1. M.E.Parsons and C.R.Ganellin, Histamine and its receptors, Br. J. Pharmacol. 147 (2006), pp. S127–S135.
2. R.Seifert, A.Strasser, E.H.Schneider, D.Neumann, S.Dove, and A.Buschauer, Molecular and cellular analysis of human histamine receptor subtypes, Trends Pharmacol. Sci. 34 (2013), pp. 33–58.
3. S.Lorenzi, M.Mor, F.Bordi, S.Rivara, M.Rivara, G.Morini, S.Bertoni, V.Ballabeni, E.Barocelli, and P.V.Plazzi, Validation of a histamine H3 receptor model through structure-activity relationships for classical H3 antagonists, Bioorg. Med. Chem. 13 (2005), pp. 5647–5657.
4. E.H.Schneider, A.Strasser, R.L.Thurmond, and R.Seifert, Structural requirements for inverse agonism and neutral antagonism of indole-, benzimidazole-, and thienopyrrole-derived histamine H4 receptor ligands, J. Pharmacol. Exp. Ther. 334 (2010), pp. 513–521.
5. J.W.Black, W.A.Duncan, C.J.Durant, C.R.Ganellin, and E.M.Parsons, Definition and antagonism of histamine H 2 -receptors, Nature 236 (1972), pp. 385–390.
6. S.J.Hill, C.R.Ganellin, H.Timmerman, J.C.Schwartz, N.P.Shankley, J.M.Young, W.Schunack, R.Levi, and H.L.Haas, International Union of Pharmacology. XIII. Classification of histamine receptors, Pharmacol. Rev. 49 (1997), pp. 253–278.
7. T.Nonaka, M.Mio, M.Doi, and K.Tasaka, Histamine-induced differentiation of HL-60 cells. The role of cAMP and protein kinase A, Biochem. Pharmacol. 44 (1992), pp. 1115–1121.
8. J.Del Valle and I.Gantz, Novel insights into histamine H2 receptor biology, Am. J. Physiol. 273 (1997), pp. G987–G996.
9. G.J.Durant, J.C.Emmett, C.R.Ganellin, P.D.Miles, M.E.Parsons, H.D.Prain, and G.R.White, Cyanoguanidine-thiourea equivalence in the development of the histamine H2-receptor antagonist, cimetidine, J. Med. Chem. 20 (1977), pp. 901–906.
10. S.F.Campos and R.Campos, Garzon Loyo, R. Cortes Gonzalez, and C. de la Rosa Laris, Inhibition of gastric secretion: Cimetidine and ranitidine, Rev. Gastroenterol. Mex. 49 (1984), pp. 145–149.
11. M.J.Daly, J.M.Humphray, and R.Stables, Inhibition of gastric acid secretion in the dog by the H2-receptor antagonists, ranitidine, cimetidine, and metiamide, Gut 21 (1980), pp. 408–412.
12. S.T.Nielsen, Inhibition of gastric acid secretion by H2-receptor antagonists, Arch. Int. Pharmacodyn. Ther. 282 (1986), pp. 151–160.
13. I.Yanagisawa, Y.Hirata, and Y.Ishii, Studies on histamine H2 receptor antagonists. 2. Synthesis and pharmacological activities of N-sulfamoyl and N-sulfonyl amidine derivatives, J. Med. Chem. 30 (1987), pp. 1787–1793.
14. J.H.Lin, Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations, Clin. Pharmacokinet. 20 (1991), pp. 218–236.
15. A.Lau, M.Tomizza, M.Wong-Pack, A.Papaioannou, and J.Adachi, The relationship between long-term proton pump inhibitor therapy and skeletal frailty, Endocrine 49 (2015), pp. 606–610.
16. M.A.GagliaJr, R.Torguson, N.Hanna, M.A.Gonzalez, S.D.Collins, A.I.Syed, I.Ben-Dor, G.Maluenda, C.Delhaye, K.Wakabayashi, Z.Xue, W.O.Suddath, K.M.Kent, L.F.Satler, A.D.Pichard, and R.Waksman, Relation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomes, Am. J. Cardiol. 105 (2010), pp. 833–838.
17. P.M.Ho, T.M.Maddox, L.Wang, S.D.Fihn, R.L.Jesse, E.D.Peterson, and J.S.Rumsfeld, Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome, JAMA 301 (2009), pp. 937–944.
18. L.B.Hough, Genomics meets histamine receptors: New subtypes, new receptors, Mol. Pharmacol. 59 (2001), pp. 415–419.
19. S.M.Foord, T.I.Bonner, R.R.Neubig, E.M.Rosser, J.P.Pin, A.P.Davenport, M.Spedding, and A.J.Harmar, International Union of Pharmacology. XLVI. G protein-coupled receptor list, Pharmacol. Rev. 57 (2005), pp. 279–288.
20. J.C.Mobarec and M.Filizola, Advances in the development and application of computational methodologies for structural modeling of G-protein coupled receptors, Expert Opin. Drug Discov. 3 (2008), pp. 343–355.
21. K.Palczewski, T.Kumasaka, T.Hori, C.A.Behnke, H.Motoshima, B.A.Fox, I.Le Trong, D.C.Teller, T.Okada, R.E.Stenkamp, M.Yamamoto, and M.Miyano, Crystal structure of rhodopsin: A G protein-coupled receptor, Science 289 (2000), pp. 739–745.
22. R.Chaudhari, A.J.Heim, and Z.Li, Improving homology modeling of G-protein coupled receptors through multiple-template derived conserved inter-residue interactions, J. Comput. Aided Mol. Des. 29 (2015), pp. 413–420.
23. S.Costanzi, G protein-coupled receptors: Computer-aided ligand discovery and computational structural analyses in the 2010s, In Silico Pharmacol. 1 (2013), p. 20.
24. S.Costanzi and K.Wang, The GPCR crystallography boom: Providing an invaluable source of structural information and expanding the scope of homology modeling, Adv. Exp. Med. Biol. 796 (2014), pp. 3–13.
25. B.Taddese, L.M.Simpson, I.D.Wall, F.E.Blaney, and C.A.Reynolds, Modeling active GPCR conformations, Methods. Enzymol. 522 (2013), pp. 21–35.
26. A.Saxena, M.Dhaon, S.Ram, M.Saxena, P.Jain, G.Patnaik, and N.Anand, Snythesis and QSAR in 2-substituted-1,2,3,4,6,7,12,12A-octahydropyrazino [2’,1’-6,1]pyrido[3,4-b]indoles-A new class of H1-antagonists, Indian J. Chem. Sec0 b-Org. Chem. Includ. Med. Chem. 22 (1983), pp. 1224–1232.
27. M.Saxena, S.K.Agarwal, G.Patnaik, and A.K.Saxena, Synthesis, biological evaluation, and quantitative structure-activity relationship analysis of [. beta.-(aroylamino) ethyl] piperazines and-piperidines and [2-[(arylamino) carbonyl] ethyl] piperazines,-piperidines,-pyrazinopyridoindoles, and-pyrazinoisoquinolines. A new class of potent H1 antagonists, J. Med. Chem. 33 (1990), pp. 2970–2976.
28. G.Patnaik, A.Saxena, M.Saxena, and R.Srimal, Antihistaminic activity of quinethindole: A 2-substituted pyrazinopyridoindole derivative, Ind. J. Exp. Biol. 30 (1992), pp. 144–146.
29. S.Gaur, P.Prathipati, M.Saxena, and A.K.Saxena, CoMFA and CoMSIA studies on a set of benzyl piperazines, piperadines, pyrazinopyridoindoles, pyrazinoisoquinolines and semi rigid analogs of diphenhydramine, Med. Chem. Res. 13 (2004), pp. 746–757.
30. A.Saxena, I.Alam, A.Dixit, and M.Saxena, Internet resources in GPCR modelling, SAR QSAR Environ. Res. 19 (2008), pp. 11–25.
31. M.Saxena, S.S.Bhunia, and A.K.Saxena, Docking studies of novel pyrazinopyridoindoles class of antihistamines with the homology modelled H(1)-receptor, SAR QSAR Environ. Res. 23 (2012), pp. 311–325.
32. S.Dove, S.Elz, R.Seifert, and A.Buschauer, Structure-activity relationships of histamine H2 receptor ligands, Mini Rev. Med. Chem. 4 (2004), pp. 941–954.
33. X.Sun, Y.Li, W.Li, Z.Xu, and Y.Tang, Computational investigation of interactions between human H2 receptor and its agonists, J. Mol. Graph. Model 29 (2011), pp. 693–701.
34. J.Zhang, T.Qi, and J.Wei, Homology modeling and antagonist binding site study of the human histamine H2 receptor, Med. Chem. 8 (2012), pp. 1084–1092.
35. J.L.Miller-Gallacher, R.Nehme, T.Warne, P.C.Edwards, G.F.Schertler, A.G.Leslie, and C.G.Tate, The 2.1 A resolution structure of cyanopindolol-bound beta1-adrenoceptor identifies an intramembrane Na+ ion that stabilises the ligand-free receptor, PLoS One 9 (2014), p. e92727.
36. C.Obiol-Pardo, L.Lopez, M.Pastor, and J.Selent, Progress in the structural prediction of G protein-coupled receptors: D3 receptor in complex with eticlopride, Proteins 79 (2011), pp. 1695–1703.
37. V.Cherezov, D.M.Rosenbaum, M.A.Hanson, S.G.Rasmussen, F.S.Thian, T.S.Kobilka, H.J.Choi, P.Kuhn, W.I.Weis, B.K.Kobilka, and R.C.Stevens, High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor, Science 318 (2007), pp. 1258–1265.
38. T.Shimamura, M.Shiroishi, S.Weyand, H.Tsujimoto, G.Winter, V.Katritch, R.Abagyan, V.Cherezov, W.Liu, G.W.Han, T.Kobayashi, R.C.Stevens, and S.Iwata, Structure of the human histamine H1 receptor complex with doxepin, Nature 475 (2011), pp. 65–70.
39. S.S.Bhunia, K.K.Roy, and A.K.Saxena, Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches, J. Chem. Inf. Model. 51 (2011), pp. 1966–1985.
40. A.K.Gupta, S.S.Bhunia, V.M.Balaramnavar, and A.K.Saxena, Pharmacophore modelling, molecular docking and virtual screening for EGFR (HER 1) tyrosine kinase inhibitors, SAR QSAR Environ. Res. 22 (2011), pp. 239–263.
41. J.Devillers, C.Lagneau, A.Lattes, J.C.Garrigues, M.M.Clémenté, and A.Yébakima, In silico models for predicting vector control chemicals targeting Aedes aegypti, SAR QSAR Environ. Res. 25 (2014), pp. 805–835.
42. A.K.Saxena, J.Devillers, A.R.Pery, R.Beaudouin, V.M.Balaramnavar, and S.Ahmed, Modelling the binding affinity of steroids to zebrafish sex hormone-binding globulin, SAR QSAR Environ. Res. 25 (2014), pp. 407–421.
43. T.U.P.ResourceThe Universal Protein, UniProt, Nucleic Acids Res 35 (2007), pp. D193–D197.
44. J.D.Thompson, D.G.Higgins, and T.J.Gibson, CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice, Nucleic Acids Res 22 (1994), pp. 4673–4680.
45. A.Fiser and A.Sali, Modeller: Generation and refinement of homology-based protein structure models, Methods Enzymol. 374 (2003), pp. 461–491.
46. R.A.Laskowski, M.W.MacArthur, D.S.Moss, and J.M.Thornton, PROCHECK: A program to check the stereochemical quality of protein structures, J. Appl. Cryst. 26 (1993), pp. 283–291.
47. Protein Preparation Wizard, Schrödinger Suite 2009.
48. MacroModel, version 9.7, Schrödinger, LLC, New York, NY, 2009.
49. LigPrep, version 2.3, Schrödinger, LLC, New York, NY, 2009.
50. Glide, version 5.5, Schrödinger, Inc., New York, NY, 2009.
51. G.Wolber and T.Langer, LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters, J. Chem. Inf. Model. 45 (2005), pp. 160–169.
52. Discovery Studio2.0, Accelrys, San Diego, CA 92121, USA.
53. J.M.Humphray, M.J.Daly, and R.Stables, Pharmacological interactions between ranitidine, cimetidine, metiamide and tiotidine at histamine H2-receptor sites in guinea-pig atria, Agents Actions 12 (1982), pp. 138–141.